and a decision was made to observe the patient overnight provided she remained haemodynamically stable. A repeat departmental scan the next morning reported "a right adnexal mass measuring 26 × 21 × 31 mm with a gestational sac plus a viable fetal pole with a crown-rump length of 8 mm compatible with a gestation of 6 weeks and 1 day". The earlier reported cyst on the right ovary was not seen. There was extensive fluid in the upper abdomen, suggestive of a ruptured ectopic pregnancy. The serum β-human chorionic gonadotrophin result was 26 679 IU/l and the haemoglobin level in the morning was 7.1 g/dl. An exploratory laparotomy confirmed the diagnosis and the patient made a good recovery following surgery.
Discussion
Organon International first introduced Implanon in the UK in September 1999. Its website states that "Implanon ® is a single-rod contraceptive implant that is inserted under the skin of the upper arm and provides highly reliable protection against pregnancy for up to 3 years". This case is presented in order to highlight the fact that this statement in terms of effective duration of use may not be applicable in HIV-positive women on antiretroviral medication.
Implanon contains 68 mg of a synthetic progestogen, etonogestrel. The implant releases approximately 40 µg etonogestrel per day, which inhibits ovulation by suppressing the luteinising hormone surge; increases the viscosity of cervical mucus, reducing sperm penetration and motility; and provides effective contraception for 3 years. Implanon is absolutely contraindicated in the presence of severe liver disease, and long-term use of liver enzyme-inducing drugs can reduce efficacy. 1 Following its introduction to the market, several early studies suggested a 100% contraceptive effectiveness of Implanon by means of ovulation suppression. One study demonstrated that the first ovulation with Implanon was after about 30 months of use. 2 A recent cohort study of Implanon users in a real-life setting in Luton, UK reported a contraceptive effectiveness of 100% for 3 years of use in their study population. 3 Contraceptive failures are now well reported in the literature. Most of the contraceptive failures have been attributed to insertion technique error (i.e. implant not found when pregnancy has been diagnosed), failure of contraceptive effect secondary to its association with an enzyme-inducing drug and untimely insertion (i.e. insertion after Day 5 of the menstrual cycle or in women who are already pregnant at the time of insertion). 4 In a postmarketing case series of more than 218 unintended pregnancies associated with Implanon in the first 3 years following its launch in Australia, the authors reported an approximate failure rate of 1 in 1000 insertions. 5 The most common reason for contraceptive failure was insertion failure. Other reasons included unknown pregnancy at the time of insertion, incorrect timing of insertion, expulsion, and interaction with hepatic enzyme-inducing medication.
The implant in the present case was clearly palpable and intact, thereby ruling out insertion technique error, breakage, expulsion, incorrect timing of insertion and unknown pregnancy at time of insertion as potential causes of contraceptive failure. The only explanation for contraceptive failure in the present case would appear to be the hepatic enzyme-inducing effect of the antiretroviral therapy, since the patient was not on any other medication apart from a Becotide inhaler for her asthma.
Efavirenz is the only component of the patient's antiretroviral regimen known to have a liver enzymeinducing effect. The nucleoside reverse transcriptase inhibitors are metabolised via a different route and thus would be unlikely to compete for the same metabolic enzymes and elimination pathways.
Efavirenz has a high affinity for binding to plasma proteins, displays a prolonged plasma half-life, is metabolised via cytochrome P450 2B6 and 3A4, and induces CYP450 activity during chronic administration. 6 Other compounds that are substrates of CYP3A4 such as progesterone, anticonvulsants and anti-tuberculosis agents may have decreased plasma concentrations when coadministered with efavirenz. Dosage adjustment is therefore necessary with the co-administered drug. Efavirenz is also known to increase the plasma concentration of ethinylestradiol, the clinical significance of which is not known. 7
Conclusions
HIV-seropositive women continue to be sexually active after diagnosis. All such women should be counselled regarding proper use and possible side effects of their chosen method(s) of contraception.
The importance of using barrier methods in addition to their primary choice of contraception cannot be overemphasised -even in those women with HIV-positive partners -in order to reduce the potential for transmission of drug-resistant virus. Condoms should be promoted and provided free of charge, since their correct and consistent use during sexual intercourse decreases the risk of transmitting HIV to the uninfected partner by up to 96% in addition to providing protection against other sexually transmitted infections and unplanned pregnancies. 8 All such women wishing to use hormonal contraceptive methods should also be given condoms and counselled as to their use, especially since protease inhibitors, rifamycins and non-nucleoside reverse transcriptase inhibitors may decrease the effectiveness of hormonal contraceptives. 7, 9, 10 Statements on funding and competing interests Funding None identified. Competing interests None identified.
